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BACKGROUND: The immuno-privileged status of the testis is essential to the maintenance of its functions,and innate
immunity is likely to play a key role in limiting harmful viral infections, as demonstrated in the rat. In men mumps
virus infects Leydig cells and has deleterious effects on testosterone production and spermatogenesis. The aim of this
study was to test whether mumps virus infection of isolated human Leydig cells was associated with an inhibition of
their innateantiviraldefences. METHODS: LeydigcellproductionofmRNAandproteinforinterferons(IFNs)andof
three antiviral proteins—2050 oligoadenylate synthetase (2050OAS), double-stranded RNA-activated protein kinase
(PKR) and MxA—was investigated, in the absence or presence of mumps virus or viral stimuli including poly I:C,
a mimetic of RNA viruses replication product. RESULTS: Stimulated or not, human Leydig cells appeared unable
to produce routinely detectable IFNs a, b and g. Although the level of PKR remained unchanged after stimulation,
the expression of 2050OAS and MxA was enhanced following either mumps virus or poly I:C exposure (P<0.05 versus
control). CONCLUSIONS: Overall, our results demonstrate that mumps virus replication in human Leydig cells is
not associated with a speciﬁc inhibition of IFNs or 2050OAS, MxA and PKR production and that these cells display
relatively weak endogenous antiviral abilities, as opposed to their rat counterparts.
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Introduction
Viral infections of the testis represent a threat to the species
as they may lead to the sexual dissemination of pathogens.
Furthermore, virus replication can result in decreased
production of spermatozoa ultimately causing sterility,
and/or testosterone deﬁciency (reviewed in Dejucq and
Jegou, 2001). The immuno-privileged status of the testis is
essential to the maintenance of its endocrine and exocrine func-
tion (Maddocks and Setchell, 1990) and its disruption through
the inﬁltration of blood-borne leukocytes associated with the
pathogen-induced inﬂammation of the testis, named orchitis,
is known to contribute to the impairment of sperm production
(reviewed in Hedger and Meinhardt, 2003). In this context,
it is important to understand whether innate immunity can
limit replication of viruses in the human testis and hence the
harmful intrusion of acquired immune cells, and how some
viruses may escape this defence system.
Interferons a/b (type I IFNs) are crucial components of the
innate immune system involved in the cellular antiviral defence
system. Following the binding of IFNs a/b to their speciﬁc
receptor, JAK/Stat signalling cascade induces the activation
of transcription of several antiviral proteins, among which
the best characterized are the 2050 oligoadenylate synthetase
(2050OAS), double-stranded RNA-activated protein kinase
(PKR) and MxA (reviewed in Stark et al., 1998; Goodbourn
et al., 2000; Sen, 2001; Katze et al., 2002). These proteins
can also be directly activated by viral gene products through
an IFN-independent pathway (reviewed in Sen, 2001).
IFN-induced proteins create an antiviral state in infected cells
by inhibiting various stages of viral replication (Stark et al.,
1998; Goodbourn et al., 2000). However, some viruses have
evolved mechanisms to counteract the antiviral host responses
(Stark et al., 1998; Goodbourn et al., 2000; Sen, 2001; Katze
et al., 2002).
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Advance Access publication on June 20, 2008We showed previously that in the rat testis exposed to a
virus the testosterone-producing Leydig cells synthesized
large amounts of IFNs a/b (Dejucq et al., 1998) as well as
of the antiviral proteins 2050OAS, PKR and MxA (Melaine
et al., 2003). Other testicular somatic cells (i.e. macrophages,
Sertoli cells and peritubular cells) were also found to display
strong antiviral responses, whereas germ cells responded very
weakly, if at all, to virus exposure (Dejucq et al., 1995,
1997, 1998; Melaine et al., 2003). Interestingly, the strong
antiviral innate immunity of the rat testis correlates to the
absence of naturally occurring viral orchitis in this animal
species. In contrast, several viruses may cause orchitis in
men. Among them, the mumps virus is well known for its
testicular tropism and for inducing inﬂammation, decreased
androgen production and degeneration of the seminiferous
epithelium that can lead to sterility (reviewed in Dejucq and
Jegou, 2001). As shown in the testicular interstitial tissue
in vivo (Bigazzi et al., 1968; Bjorvatn, 1973), the mumps
virus has been found to replicate in Leydig cells and be
associated with a decrease in testosterone production in vitro
(Le Gofﬁc et al., 2003). Interestingly, the latter study reported
that mumps virus infection of human Leydig cells did not
seem to induce IFN production by these cells (Le Gofﬁc
et al., 2003), in contrast to their rat counterpart exposed to
another paramyxoviridae virus, the Sendai virus (Dejucq
et al., 1998). To determine whether the deleterious effects of
the mumps virus on the human testis functions resulted from
its ability to circumvent antiviral responses, the present study
aimed at comparing the antiviral defence capabilities of
human Leydig cells following either mumps virus infection
or exposure to other viral stimuli including poly I:C, a
mimetic of RNA viruses replication product that, unlike live
viruses, is devoid of inhibitory effects on the IFN system.
Materials and Methods
Antibodies, cells and virus
Mouse monoclonal antibodies against mumps virus proteins (clone
11–046) and herpes simplex virus type 2 (HSV-2) glycoprotein
(clone CHA437) were purchased from Argene SA (Varilhes,
France) while rabbit polyclonal anti-human MxA (Ronni et al.,
1993) and Annexin V (Casado et al., 1999) were generously provided
by Dr Ilkka Julkunen (Department of Microbiology, National Public
Health Institute, Helsinki, Finland) and Dr Franc ¸oise Russo-Marie
(Institut Cochin, Paris, France), respectively. Mouse monoclonal anti-
human PKR (Francois et al., 2000) and LH receptor (clone LHR29)
(Meduri et al., 1997) were, respectively, gifts of Dr Eliane Meurs
(Pasteur Institute, Paris, France) and Pr Edwin Milgrom (INSERM
U135, Le Bice ˆtre hospital, Saint Cloud, France). MRC-5, 293T and
Vero cell lines were obtained from the European Collection of Cell
Cultures (http://www.ecacc.org.uk). Martin Darby bovine kidney
(MDBK) cell line and peripheral blood mononuclear cells (PBMCs)
were obtained from the University Hospital (Pontchaillou, Rennes,
France) and maintained as previously described (Ruffault et al.,
1992, 1995). The Vit-MA strain of mumps virus, isolated from a
patient at the Reims hospital (France), was ampliﬁed in Vero cells
and titrated by plaque assay. Mumps virus titre was expressed
as plaque forming units (PFU) as previously described (Le Gofﬁc
et al., 2003). Titrated stock of Sendai virus, vesicular stomatitis
virus (VSV) and HSV-2 were obtained from the University Hospital
(Pontchaillou, Rennes, France). Human immunodeﬁciency virus
(HIV)-2ROD gp105 (EVA621) was produced using a baculovirus
expression system (EU program EVA, MRC, UK).
Isolation and culture of human Leydig cells
The protocol was approved by the local ethics committee of University
of Rennes and informed consent was obtained from the donors.
Normal testes, obtained from prostate cancer patients not subjected
to any hormone therapy (age range 60–80 years), were transported
on ice immediately after orchidectomy in fresh medium. The clinical
status of the patients revealed no reproductive abnormalities or testi-
cular infections. Leydig cell isolation was performed as previously
described (Willey et al., 2003). The occurrence of fully developed
spermatogenesis was veriﬁed by transillumination examination of
the freshly isolated seminiferous tubules (Willey et al., 2003; Roulet
et al., 2006). In order to eliminate the remaining monocytes/
macrophages, a depletion step was performed using magnetic CD14
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity
of Leydig cells preparations was .98%, as assessed by histochemical
staining for 3b-hydroxysteroid dehydrogenase (HSD) and ﬂow
cytometry analysis for LH receptor (Meduri et al., 1997; Willey
et al., 2003). The contaminants were a few CD45 positive leukocytes,
alkaline phosphatase positive peritubular cells (Anthony and Skinner,
1989) and round non-adherent haploid to tetraploid germ cells
identiﬁed on their morphological appearance and ploidy proﬁle in
ﬂow cytometry (Pﬁtzer et al., 1982) (,1% each).
Cell stimulation and Leydig cell infection
Isolated Leydig cells and cellular positive controls (PBMC or MRC-5)
were incubated for various periods of time (as speciﬁed in the text and
ﬁgure legends) with either 25 mg/ml of synthetic double-stranded
RNA (poly I:C; Amersham Biosciences, Piscataway, NJ, USA)
(optimum concentration determined by preliminary dose–response
experiments using 1–100 mg/ml of poly I:C) or 1000 U/ml of recom-
binant IFN a2a (PBL Biomedical laboratories, NJ, USA) (Der et al.,
1998). In addition, primary Leydig cell cultures were exposed or not
(control) to mumps virus [multiplicity of infection (m.o.i) of 0.1
PFU/cell] (Le Gofﬁc et al., 2003) for 6–96 h as speciﬁed in the
text, HSV-2 [m.o.i of 10 TCID50 (tissue culture infectious dose
affecting 50% of the cultures)/cell] for 20 h (Malmgaard et al.,
2004), or to the envelope glycoprotein (gp105) from HIV-2ROD
(1 mg/ml for 20 h) (Gessani et al., 1994), a virus previously shown
to infect Leydig cells (Willey et al., 2003). Productive infection of
Leydig cells by mumps virus was consistently observed between 72
and 96 h post-viral exposure. Infected cells formed syncitia, in the
cytoplasm of which mumps proteins were detected by immunocyto-
chemical staining as previously described (Le Gofﬁc et al., 2003).
Leydig cells were also permissive to HSV-2 replication as assessed
by their rounded morphological appearance and positive immunocyto-
chemical staining with anti-HSV-2 protein antibodies.
IFN detection: enzyme-linked immunosorbent assay and bioassay
Cultured cell supernatants from at least three different donors were
assayed using enzyme-linked immunosorbent assay (ELISA) kits
speciﬁc for IFNs a (subtypes aA, a2, aA/D, aD, aK and a4b),
IFN b (both from Biosource Europe SA, Nivelles, Belgium) and
IFN g (CYTELISA, Cytimmune Science Inc.
w, MD, USA), with a
sensitivity range of 10–500 pg/ml, 8.25–660 UI/ml and 7.81–
500 pg/ml, respectively, and an inter-assay accuracy of less than
10%, 15% and 11% and an intra-assay accuracy of 5%, 9% and 7%
for IFNs a, IFN b and IFN g, respectively. The bioactivity of IFNs
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in three independent experiments using a standard microcytopathic
inhibition assay derived from the method of Rubinstein et al.
(1981), using MDBK cells (a bovine kidney cell of epithelial origin
expressing the IFN a/b receptor), VSV as the challenge virus and
recombinant IFN a2a (PBL Biomedical Laboratories) to standardize
inter-assay variations, as previously described (De Maeyer et al.,
1982). For both techniques, a supernatant of PBMC cells infected
for 48 h by Sendai virus was used as a positive control.
RNA extraction and cDNA synthesis
Total RNA was extracted from cultured Leydig cells using the
Rneasy mini kit (Qiagen SA, Courtaboeuf, France) according to the
manufacturer’s instructions. RNA was then submitted to DNase
digestion to remove contaminating genomic DNA and reverse-
transcribed into complementaryDNA (cDNA) as previously described
(Willey et al., 2003).
RT–PCR analysis
Forty nanogram of equivalent RNA was used in each RT–PCR.
Ampliﬁcation was carried out using 35 cycles [except 30 cycles for
human IFN a/b receptor, b-actin and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)] in a Trio-Thermoblock thermocycler
(Biometra, Goettingen, Germany) as previously described (Dejucq
et al., 1998). Primers used for RT–PCR were either described
previously [human IFN a/b receptor (Lutfalla et al., 1992), IFN g
(Taya et al., 1982), IFN a1 (Nagata et al., 1980), interleukin (IL)-6
(Cudicini et al., 1997), b-actin (Ponte et al., 1984)] or designed
according to the Primer 3 software (Rozen and Skaletsky, 2000), all
presented as forward (50) then reverse (30), and 50 to 30: human consen-
sus IFN a (designed to detect 12 IFN a sub-types): 50 primer,
CTGTCCTCCATGAGVTG (V is a degenerate base coding for
either A, C or G. Oligonucleotides generated from this sequence are
a heterogenous population of these three distinct species); 30 primer,
CATGATTTCTGCTCTGACAACC; human IFN b:5 0 primer, TCA
GAGCTCCTGTGGCAAT; 30 primer, CTGACTATGGTCCAGGC
ACA; human CD45: 50 primer, TCAGGGAAAGAAAGTGGTGC, 30
primer, AAGAAGGAGCCCTGATTTCC; human 3b-HSD: 50 primer,
GCCTGTTGGTGGAAGAGAAG; 30 primer, TGTGGGT CTTAACG
CACAAG; human TLR3: 50 primer, CTTAGCACGGCTCTGGAAAC,
30 primer, AAGAGTTCAAAGGGGGCACT; human TLR7: 50 primer,
TGCTCTGCTCTCTTCAACCA, 30 primer, TGGTCCAGTCTGTGAA
AGGA; human TLR8: 50 primer, TGCTGCAAGTTACGGAATGA, 30
primer, ATTTTGCAGCCCTTGAAATG; human GAPDH: 50 primer,
TGGATATTGTTGCCATCAATGACC, 30 primer, GATGGCATGG
ACTGTGGTCATG. The ampliﬁcation products were validated by
direct sequencing using an automated DNA sequencer (373 DNA
sequencer, Applied Biosystems, Foster city, CA, USA). cDNA integ-
rity, as well as absence of genomic DNA contamination, was checked
by GAPDH ampliﬁcation with primers designed in two subsequent
exons, thus generating different sizes for genomic DNA versus
cDNA ampliﬁcation products.
Quantitative real-time PCR
Relative quantiﬁcation of mRNAs encoding PKR, MxA and the 40 kD
isoform of 2050OAS (2050OAS p40) was performed using the TaqMan
technology. PCR was carried out on 4 and 40 ng of equivalent
RNA run in duplicate, with the ABI7500 (Applied Biosystems),
using commercially available target probes (with the exception
of the 2050OAS p40) and master mix (Applied Biosystems):
Hs00169345_m1 (PKR), Hs00182073_m1 (MxA), Hs99999901_s1
(ribosomal 18S). PCR primers and the TaqMan probe for the p40
2050OAS were designed using the primer Express software (Applied
Biosystems) and purchased from Eurogentec (Angers, France) and
Applied Biosystems, respectively. The relative gene expression in
four independent cultures was normalized to the level of ribosomal
18S by the use of the comparative CT method, as described in the
Applied Biosystems User bulletin no. 2 (P/N 4303859). The
non-parametric unpaired Kruskal–Wallis test was used to assess
differences between control and stimulated cultures. P , 0.05 was
considered statistically signiﬁcant.
Western blotting
Leydig cell cultures were lysed using radioimmunoprecipitation assay
(RIPA) buffer supplemented with 5 ml/ml protease inhibitor cocktail
and 1 mM 4-(2-Aminoethyl) benzenesulphonyl ﬂuoride hydrochloride
(AEBSF) (both Sigma). Protein quantiﬁcation, electrophoresis on
polyacrylamide gel and electro-transfer were performed as previously
described (Guillaume et al., 2001). The membrane was then blocked
overnight at 48C with tris-buffered saline (TBS) 0.01% Tween 20
(TBST) supplemented with 5% non-fat milk. Following washes in
TBST, the membrane was incubated for 1–2 h at room temperature
in 1% non-fat milk-TBST containing the primary antibody at the fol-
lowing dilutions: MxA 1:25 000; PKR 1:200; Annexin V 1:15 000.
Bands were visualized using the appropriate horseradish peroxidase
secondary antibody (Jackson Immunoresearch Laboratories Europe,
Suffolk, UK and Amersham Biosciences) and the enhanced chemilu-
minescence (ECL)þ system, according to the manufacturer’s instruc-
tions (ECL plus, Amersham Biosciences).
Lentiviral vector production
The transfer vector plasmid pHRsin-cppt-SEW containing the
enhanced green ﬂuorescent protein (eGFP) reporter gene under the
control of the ubiquitous spleen focus forming virus (SFFV) promoter
(Demaison et al., 2002), the pMD.G plasmid encoding the VSV
envelope (Naldini et al., 1996) and the multideleted packaging
plasmid pCMV8.91 (Gray et al., 1998) were generously provided by
Dr Stuart Neil (UCL, London). The IFNb-pGL3 plasmid containing
the luciferase reporter gene under the control of the human IFN b
promoter (Lin et al., 2000) was a gift from Dr Eliane Meurs. The con-
struction of the pHRsin-cppt-lark-IFN b vector plasmid was realized
in the viral vector production plate-forme (INSERM U649, Nantes,
France). Brieﬂy, the SFFV strain P long terminal repeat sequence
was removed from pHRsin-cppt-SEW using BamH1 and EcoR1
enzymes (fragment 7748–8256; ﬁlled with klenow enzyme) and
subsequently replaced by the IFN b promoter fragment, previously
removed from the IFN b-pGL3 plasmid using the EcoR1 enzyme
(fragment 24–327; ﬁlled with klenow enzyme).
Pseudotyped vectors were produced by transient lipofectamine
transfection (Invitrogen SARL, Cergy Pontoise, France) of three plas-
mids into 293T cells: pHRsin-cppt-lark-IFNb or pHRsin-cppt-SEW
transfer vector plasmid, the packaging construct plasmid pCMV8.91
and the VSV-G envelope plasmid pMD.G, and stocks of virus titrated
as previously described (Demaison et al., 2002). For the pseudotyped
lentiviral vector particles containing the pHRsin-cppt-lark-IFNb
plasmid, the eGFP expression was measured following stimulation
with poly I:C (25 mg/ml).
Transduction of Leydig cells by lentiviral vectors
Puriﬁed Leydig cells plated for 48 h in a 12-well plate were infected
with pseudotyped lentiviral vector particles containing either the
pHRsin-cppt-lark-IFNb plasmid (called IFN b promoter below) or
the pHRsin-cppt-SEW plasmid (called SFFV promoter below) at an
m.o.i of 40, in Dulbecco’s modiﬁed Eagle’s medium F12 medium
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the pseudotyped lentiviral vector containing the SFFV promoter (posi-
tive control), c.100% of the cells were positive for eGFP expression as
assessed by ﬂuorescent microscopy observation. This time point was
chosen to start stimulating the IFN b promoter-transduced Leydig
cells with 25 mg/ml of poly I:C or with 20 mg/ml of lipopolysacchar-
ide (LPS) (Sigma). Following stimulation, eGFP expression was
checked regularly (every 6–12 h) for several days under a ﬂuorescent
microscope. Leydig cells were identiﬁed by light microscopy and
by ﬂuorescent immunostainingfor LHreceptor expression usinga pre-
viously described anti LH receptor antibody (Le Gofﬁc et al., 2003)
and a secondary rhodamine conjugated donkey anti-mouse IgG
(dilution 1/50; Jackson Immunoresearch Laboratories Europe).
Results
Absence of IFNs in human Leydig cells
Using speciﬁc ELISA assays, neither unstimulated Leydig cells
nor Leydig cells from three different donors exposed to mumps
virus for various durations (6, 12, 24, 48 or 72 h) were found to
produce IFNs a, b or g. To determine whether this lack of
detection was speciﬁc to mumps infection, Leydig cells were
stimulated with poly I:C, a well-known potent inducer of
IFNs a/b. Very low concentrations of IFNs a and b (respect-
ively, 14 and 13 pg/ml), at the limit of detection of the assay,
were occasionally detected in cultures exposed to poly I:C for
6–24 h. Using a bioassay based on the detection of the antiviral
properties of IFNs a/b (Rubinstein et al., 1981), Leydig cell
supernatants from at least three independent cultures incubated
intheabsenceor presence ofmumpsvirus orpolyI:Cstimulation
for 20 h were accordingly devoid of any signiﬁcant activity.
Similarly, Leydig cell exposure to either HSV-2 or HIV-2
gp105 did not lead to any detectable antiviral activity in the
cell culture supernatants, further indicating that the lack of IFN
production by Leydig cells was independent of the nature of
the viral stimuli. The results of our assays were in line with
the data obtained by RT–PCR which showed absence or very
low IFN a, b and g transcript levels in our Leydig cell cultures
stimulated by poly I:C for 5 or 10 h (Fig. 1). In contrast, tran-
scripts for the speciﬁc Leydig cell marker 3bHSD and for IL6
that are constitutively expressed by Leydig cells (Cudicini
et al., 1997) were consistently detected (Fig. 1). Thus, the very
weak production of IFNs a/b detected in some Leydig cell
cultures stimulated by poly I:C was very likely due to the few
contaminating leukocytes (,1%) present in our Leydig cell
preparations. Viral RNA sensors are known to be essential to
the induction of transcription of IFN and IFN-induced genes in
virus-infected or poly I:C-stimulated cells (reviewed in Sen,
2001). We thus looked for their expression in Leydig cells.
Using RT–PCR, we failed to detect transcripts encoding the
viral single-stranded RNA sensors TLR7/8 in three independent
Leydig cells preparations (Fig. 2). However, a strong expression
of the poly I:C agonist TLR3 mRNA was demonstrated in all
Leydig cell cultures tested (Fig. 2). TLR3 has been demonstrated
to be necessary for the recognition of poly I:C by different cell
types (Alexopoulou et al., 2001). These results suggest that
although Leydig cells may not be equipped to recognize single-
stranded RNA viruses such as the mumps virus, their lack/poor
IFN expression in response to poly I:C is unlikely to result from
absence of recognition.
To further test the ability of Leydig cells to activate the tran-
scription of IFN genes, Leydig cell cultures were transduced
with either a lentivector containing the eGFP reporter gene
under the control of either an exogenous IFN b promoter or
Figure 1: IFNs a, b, g and cell marker transcripts detection in
Leydig cells.
RT–PCR was performed to detect mRNAs encoding: a consensus
region for the 12 human IFNs a, IFN b, IFN g, CD45 (haematopoietic
cell marker), 3b-HSD (Leydig cell marker), IL-6 (produced by Leydig
cells) (all 35 cycles of PCR) and b-actin (30 cycles) in human Leydig
cell cultures stimulated or not (control) for 5–10 h by poly I:C. For
each mRNA sample, both a reverse transcriptase (RT) reaction (þ)
and a negative control reaction without RT (2) were performed
(Cþ: positive control represented by PBMC stimulated 24 h by poly
I:C; C2: negative control).
Figure 2: TLRs expression by human Leydig cells.
RT–PCR was performedto detectmRNAs encodingTLR3,TLR7 and
TLR8 in independent Leydig cell cultures from three donors (Leydig
C1–3) (Cþ: positive control represented by PBMC stimulated for
24 h by poly I:C; C2: negative control).
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tive control to assess the efﬁcacy of transduction in Leydig
cells. In addition, the functionality of these two constructs
was veriﬁed by checking eGFP ﬂuorescence in transduced
293T cells: 293T cells transduced with the ubiquitous SFFV
promoter were consistently ﬂuorescent in the absence of stimu-
lation (Fig. 3A and B) whereas 293T transduced with the IFN b
promoter displayed ﬂuorescence when exposed to poly I:C
(Fig. 3E and F), demonstrating the validity of the two con-
structs. Similarly, a large majority of Leydig cells transduced
with the SFFV promoter were positive for eGFP expression
(Fig. 3C and D), thus showing the efﬁcacy of transduction in
this cell type. In contrast, ﬂuorescence was never detected in
human Leydig cell cultures transduced with the IFN b promo-
ter and exposed to poly I:C for various durations (Fig. 3G–I).
We additionally tested the effect of stimulation by LPS (a
potent bacterial IFN a/b inducer) on IFN b promoter’s trans-
duced Leydig cells, but no ﬂuorescence was ever observed
(data not shown). These results show a lack of activation of
the exogenous IFN b promoter in human Leydig cells in
response to different stimuli, which explains the absence of
IFN expression in stimulated Leydig cells.
Presence ofPKR, MxAand p40 2050oas in human Leydig cells
Whether poly I:C or exogenous IFN a stimulation of Leydig
cells would lead to the production of antiviral proteins and
how it would compare with mumps virus infection was then
investigated. Quantitative RT–PCR showed that the transcripts
levels of PKR, MxA and p40 2050OAS were consistently
enhanced in MRC-5 cells exposed to poly I:C, used as a posi-
tive control (Fig. 4). The constitutive low Leydig cell PKR
transcriptional levels remained unchanged following exposure
to either poly I:C or IFN a for 16 h or to mumps virus for 36 or
72 h (Fig. 4). In contrast, a signiﬁcantly increased expression of
p40 2050OAS transcriptswas observed in Leydig cellsexposed to
either poly I:C or IFN a for 16 h. MxA mRNA expression was
also signiﬁcantly enhanced in response to IFN a and was mar-
ginally stimulated by poly I:C (Fig. 4). Of note, however, is
that their maximum induction levels were always much lower
than those in stimulated MRC-5. Following 72 h of mumps
virus exposure, MxA and 2050OAS transcripts were signiﬁcantly
stimulated, in the same order of magnitude as with poly I:C. In
contrast, no induction was observed at 36 h post-infection,
suggesting that viral replication triggered the effect (Fig. 4).
These results were substantiated at the protein level as Leydig
cell MxA levels appeared stimulated after exposure to either
poly I:C or IFN a for 24 h. This stimulation was maintained
for up to 72 h (Fig. 5). Mumps virus also enhanced MxA
protein expression from 72 h up to 96 h post-exposure (Fig. 5).
In contrast, the constitutive expression of PKR by Leydig cells
was not modiﬁed by any of those stimulations (Fig. 5).
Figure 3: Transduction of human Leydig cells with an exogenous
IFN b promoter and poly I:C stimulation.
293T cells (A and B) and human Leydig cells (C and D) were trans-
duced for 48 h with a VSV pseudotyped vector construct containing
the enhancer region of the ubiquitous spleen focus forming virus
(SFFV) promoter inserted upstream of the eGFP open reading frame
(positive control). The efﬁcacy of transduction was assessed by check-
ing eGFP ﬂuorescence which appeared at 3–4 days post-transduction,
in both 293T cells (A and B) and Leydig cells (C and D). At this time
point, 293T cells (E and F) and Leydig cells (G–I) transduced with
the IFNb promoter were stimulated with poly I:C. eGFP expression
was then checked regularly (every 6–12 h) for up to 5 days. Leydig
cells were identiﬁed on morphological criteria (C and G) and by
immunostaining for LH receptor (I). Although ﬂuorescence was con-
sistently detected in IFN b promoter-transduced 293T cells stimulated
with poly I:C, this stimulus had no effect on the transduced Leydig
cells. The results presented are representative of three independent
Leydig cell cultures.  200 magniﬁcation.
Figure 4: Quantiﬁcation of transcripts encoding antiviral proteins in
human Leydig cells exposed to mumps virus, poly I:C or IFNa.
Real-time quantitative RT-PCR analysis of double-stranded RNA-
activated protein kinase (PKR), MxA and the 40 kD isoform of 2050
oligoadenylate synthetase (p40 2050OAS) transcript expression in
human Leydig cells stimulated by poly I:C (25 mg/ml), IFN a
(1000 U/ml) or infected by the mumps virus (multiplicity of infection
0.1 PFU/cell) for the indicated durations. The results of independent
Leydig cell cultures from four donors were pooled (+SEM). MRC-5
cells stimulated by poly I:C were used as a positive control. Stars indi-
cate statistical difference between controls and stimulated cultures
(Kruskal–Wallis test, **P , 0.05, *P , 0.15).
Response of human Leydig cells to mumps virus infection
2099Discussion
Within the testis, the testosterone-producing Leydig cells play
crucial paracrine and endocrine roles in the maintenance of
spermatogenesis. Being strategically located in the vicinity of
interstitial tissue blood vessels, these cells represent the ﬁrst
testicular line of defence against blood-borne viruses. Indeed,
in the rat, Leydig cells exhibit high antiviral activities
(Dejucq et al., 1998; Melaine et al., 2003) and are not known
to be infected by any viruses. In men, mumps virus causes
disruption of spermatogenesis (Dejucq and Jegou, 2001).
Isolated human Leydig cells have been shown to support
mumps virus replication, leading to a fall in testosterone
production (Le Gofﬁc et al., 2003).
In our attempt to address the differences in infectivity
between human and rat testis, we demonstrate here that, in
contrast to the rat Leydig cells, human Leydig cells do not
represent a signiﬁcant source of IFNs a, b and g in vitro,
whether exposed to different viral stimuli, including mumps
virus or to poly I:C, or not. This reinforces previous obser-
vations from our laboratory about the lack of IFN a/b
production in response to mumps infection (Le Gofﬁc et al.,
2003) and demonstrates that this effect is not speciﬁc to
mumps virus infection. This unusual response of Leydig cells
is very unlikely to be due to the age of the donors as their
testes displayed full spermatogenesis as assessed by transillu-
mination, a cardinal criteria to establish the functioning of
the testis and therefore of Leydig cells. Furthermore, our
Leydig cell preparations expressed IL-6 mRNA, similar to
Leydig cells obtained from younger donors (Cudicini et al.,
1997). Although the donors had prostate cancer, this cancer
has never been reported to impact on testis function. The
testis is a rare site for prostate cancer metastasis and all the
testes samples used in this study displayed normal morphology.
A whole transcriptomic analysis on testes obtained from
prostate cancer patients and from vasectomized men as well
as normal versus cancerous prostate did not show any major
alterations in testicular gene expression in prostate cancer
patients (F. Chalmel, personal communication). In fact, testes
are removed in hormone-dependent prostate cancer patients
as they represent the main source of testosterone favouring
the growth of the tumour, further attesting proper Leydig cell
function. Since IFN g is usually the product of specialized
immune cells, its absence in human Leydig cells was not
unexpected. In contrast, the very weak/lack of production of
IFNs a/b by Leydig cells following poly I:C stimulation was
surprising as poly I:C represents a potent inducer of IFNs
a/b in most eukaryotic cells studied (reviewed in Goodbourn
et al., 2000; Katze et al., 2002; Hengel et al., 2005). Other viral
stimuli (HSV-2, HIV-2 gp105) also failed to induce IFN a/b
production by Leydig cells, further indicating that human
Leydig cells are not IFN producers. We also demonstrated
that the lack of IFN b is not due to a defective endogenous
IFN b gene or to high IFN b mRNA instability when we
showed that poly I:C or LPS stimulation of Leydig cells
transduced with an exogenous IFN b promoter failed to
trigger transcriptional activation, while both poly I:C and
LPS respective recognition receptors and signalling pathways
(reviewed in Uematsu and Akira, 2007) are nevertheless
functional. Thus, LPS is able to enhance human Leydig cell
IL-1 and IL-6 (Cudicini et al., 1997) and these cells express
the poly I:C sensor TLR3 transcript and produce antiviral
proteins following poly I:C exposure. In most body cells,
including the ﬁbroblastoid cell types to which Leydig cells
belong, the expression of both IFN b and a subset of IFN-
stimulated genes (ISGs) has been shown to be induced early,
whereas the expression of the full spectrum of IFNs and
ISGs occurs as a second wave dependent on IFN b secretion
(Goodbourn et al., 2000; Hiscott, 2007). Therefore, it is poss-
ible that the lack of Leydig cell IFN b prevents the activation
of IFN a genes and ISGs that are not directly activated by
viral infection. The repression of the IFN b gene in Leydig
cells could be due to either a lack in one or several transcription
factors (reviewed in Hiscott, 2007), or to speciﬁc negative
factor(s), as the human IFN b promoter is constitutively
under negative control and a large number of repressors have
been described in various cell types (Lopez and Navarro,
1998; Nourbakhsh and Hauser, 1999; Ren et al., 1999), some
of them preventing IFN induction following virus or poly I:C
stimulation (Barlow et al., 1984).
In humans, other type I IFNs (v, 1, k) have been described in
particular cell types (Samarajiwa et al., 2006). The negative
results obtained with the bioassay used in this study, which is
Figure 5: Antiviral proteins expression in human Leydig cells
exposed to mumps virus, poly I:C or IFNa.
Western-blot analysis of PKR and MxA protein expression in Leydig
cells in the absence (2) or presence (þ) of IFN a (MxA and PKR),
poly I:C (MxA) (24–72 h) or mumps virus (MxA) (24–96 h).
Cþ: positive control represented by PBMC stimulated for 24 h with
poly I:C. Annexin V represents the loading control. The results pre-
sented are representative of independent Leydig cell cultures from
three donors.
Le Tortorec et al.
2100able to detect all functional type I IFNs as they all bind to the
same receptor, indicated that indeed human Leydig cells are
very unlikely type I IFNs producers with antiviral activities.
A newly discovered third type of IFNs (IFNs l) shares with
IFNs a/b the same Jak/Stat signalling pathway, driving
expression of a common set of genes, and exhibits similar
antiviral activity (Uze and Monneron, 2007). Since IFNs l
bind toa distinct membrane receptor,they would not be detected
in the bioassay used here. However, to date IFNs l have never
been reported to be selectively induced compared with IFNs
a/b. These different IFNs appear to be co-produced in response
to all inducers studied, strongly suggesting IFNs a/b and l are
regulated by a common mechanism (Uze and Monneron, 2007).
Therefore, although IFNs l production by Leydig cells cannot
be excluded, it seems unlikely in light of the current knowledge.
In order to control infection, Leydig cells may display
antiviralresponsesinanIFN-independentfashion.Alternatively,
the antiviral state of Leydig cells could rely on IFN secretion by
neighbouring cells. To test these hypotheses, we investigated the
ability of Leydig cells, stimulated or not, to produce the three
well-characterized human proteins playing a major role in
regulating virus infection, namely PKR, 2050OAS and MxA
(Stark et al., 1998; Goodbourn et al., 2000; Sen, 2001; Katze
et al., 2002) in response to poly I:C, mumps virus or exogenous
IFNa. All stimuli increased expression of MxA and 2050OAS,
whereas PKR remained unchanged. Although the same antiviral
protein expression proﬁles were observed in the three conditions
tested, the kinetics of induction differed between poly I:C /IFN
a and mumps virus. The delayed response observed following
virus exposure suggests that viral replication is needed for the
stimulated 2050OAS and MxA expression to occur, probably
via products of mumps virus replication (most likely dsRNA).
Since Leydig cell IFN production was never detected following
mumps virus infection, the virus probably directly stimulates
MxA and 2050OAS transcription. The fact that mumps virus is
known in other systems to impair IFNs a/b and g signalling
(Kubota et al., 2001, 2002, 2005), leading to poor induction
of 2050OAS, PKR and MxA after IFN treatment (Fujii et al.,
1999), further sustains the hypothesis of an IFN-independent
pathway in human Leydig cells. Direct induction by viruses or
poly I:C of a subset of ISGs, including 2050OAS (Grandvaux
et al., 2002) and MxA (Nicholl et al., 2000; Preston et al.,
2001), has been previously shown in the absence of IFN
(reviewed in Sen, 2001; Hengel et al., 2005). When compared
with poly I:C or IFN a stimulation, we observed no inhibition
of the expression of the antiviral proteins studied following
mumps virus infection of Leydig cells. The failure of these two
proteins to prevent mumps replication could be due to their
delayed induction, although we cannot rule out a block of their
functions by mumps virus proteins. However, this feature,
described for several viruses, has never been reported for
mumps virus (reviewed in Goodbourn et al., 2000; Sen, 2001).
PKR is generally present at low levels in a number of cell
types, its expression being increased by IFN (Le Page et al.,
2000). However, IFN stimulation of human Leydig cells did
not lead to an enhanced PKR mRNA and protein expression.
Similarly, neither poly I:C nor mumps virus modiﬁed PKR
constitutive expression. Thus, rather than virus-induced
speciﬁc inhibitions of the antiviral responses of Leydig cells,
the combined lack of IFN expression, basal low levels of
PKR refractory to stimulation, together with the delayed stimu-
lation of p40 2050OAS and MxA expression could create the
environment favourable to mumps virus replication.
Systemic treatment with IFN a has been described as
beneﬁcial in three studies on patients with mumps orchitis: the
occurrence of testicular atrophy and subsequent infertility was
prevented in all patients tested (Erpenbach, 1991; Ruther et al.,
1995; Ku et al., 1999). This beneﬁt may arise from the develop-
ment of an antiviral state prior to mumps virus infection in
Leydig cells that are, as demonstrated by our results, responsive
to exogenous IFN a, thus compensating for their delayed
expression of antiviral proteins that, in the absence of IFN
signalling, only occurs secondary to mumps replication. IFN a
treatment may limit Leydig cell infection and hence the spread
of the virus in the testis. This in turn would reduce tissue inﬂam-
mation and consecutive testicular atrophy leading to sterility.
In summary, mumps virus replication inLeydig cells was not
associated with a speciﬁc inhibition of IFNs or 2050OAS, MxA
and PKR production. Compared with their rat counterparts
(Dejucq et al., 1995, 1997, 1998; Melaine et al., 2003),
our study reveals that human Leydig cells have relatively
weak antiviral capabilities (absence of IFN production) and
delayed responses to infection. Thus in the rat, several
somatic testicular cell types, among which the most potent
was Leydig cells, were able to produce high levels of IFNs
and antiviral proteins in response to Sendai virus—a virus
that belongs to the same viral family as the mumps virus
(paramyxoviridae). Whether other human testicular cell types
(e.g. resident macrophages, Sertoli cells, as identiﬁed in the
rat) display stronger innate defences or whether the human
testis as a whole possesses weaker antiviral capacities than
the rat testis, remains to be investigated.
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